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Abstract
Background: Humanized mice generate a lymphoid system of human origin subsequent to transplantation of human
CD34+ cells and thus are highly susceptible to HIV infection. Here we examined the efficacy of antiretroviral treatment (ART)
when added to food pellets, and of long-acting (LA) antiretroviral compounds, either as monotherapy or in combination.
These studies shall be inspiring for establishing a gold standard of ART, which is easy to administer and well supported by
the mice, and for subsequent studies such as latency. Furthermore, they should disclose whether viral breakthrough and
emergence of resistance occurs similar as in HIV-infected patients when ART is insufficient.
Methods/Principal Findings: NOD/shi-scid/ccnull (NOG) mice were used in all experimentations. We first performed
pharmacokinetic studies of the drugs used, either added to food pellets (AZT, TDF, 3TC, RTV) or in a LA formulation that
permitted once weekly subcutaneous administration (TMC278: non-nucleoside reverse transcriptase inhibitor, TMC181:
protease inhibitor). A combination of 3TC, TDF and TMC278-LA or 3TC, TDF, TMC278-LA and TMC181-LA suppressed the
viral load to undetectable levels in 15/19 (79%) and 14/14 (100%) mice, respectively. In successfully treated mice,
subsequent monotherapy with TMC278-LA resulted in viral breakthrough; in contrast, the two LA compounds together
prevented viral breakthrough. Resistance mutations matched the mutations most commonly observed in HIV patients
failing therapy. Importantly, viral rebound after interruption of ART, presence of HIV DNA in successfully treated mice and in
vitro reactivation of early HIV transcripts point to an existing latent HIV reservoir.
Conclusions/Significance: This report is a unique description of multiple aspects of HIV infection in humanized mice that
comprised efficacy testing of various treatment regimens, including LA compounds, resistance mutation analysis as well as
viral rebound after treatment interruption. Humanized mice will be highly valuable for exploring the antiviral potency of
new compounds or compounds targeting the latent HIV reservoir.
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Introduction
The HIV pandemic continues to spread. Even in the United
States and Europe with their relative universal access to combined
anti-retroviral treatment (ART), the prevalence of HIV-infected
people is increasing. The 2nd and 3rd generation antivirals are
very efficacious. The life expectancy of treated HIV-infected
individuals has significantly improved over the last two decades [1]
and, in turn, has contributed to the increasing prevalence.
However, ART has significant shortcomings, including adverse
events, psychological dependence, life-long adherence and cost.
Incomplete adherence results in the emergence of drug-resistant
HIV strains. Novel and simpler treatment strategies and, in the
best-case scenario, a cure are needed.
The HIV pandemic started with an ancestral SIV from a non-
human primate crossing into humans [2], and thus, it is not
surprising that HIV replication is limited to human and non-
human primate cells. Mouse models of HIV infection have been
generated by engrafting human lymphoid tissue into SCID mice
[3] and are receptive to HIV [4]. For example, SCID mice
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transplanted with fetal liver (liv) and thymus (thy) tissue were very
valuable for studying various aspects of HIV pathogenesis,
including HIV-induced pathology in the thy/liv implant, screen-
ing anti-viral compounds and hematopoietic stem cell–based gene
therapy [5]. However, these studies are limited to the thy/liv
implant.
Development of a human adaptive immune system in cord
blood cell–transplanted mice [6] renewed the interest in
humanized mice (hu mice): hematopoietic CD34+ cells were
preferentially transplanted into the liver of newborn mice or i.v.
at older age. The mice develop a lymphoid-like system of human
origin with T and B cells, monocytes, plasmacytoid and
conventional DCs, thymus and lymph nodes [7]. Their mature
T cells have a broad Vb repertoire, and more than 40% of T
cells display a naive phenotype [6]. This breakthrough was only
realized through the development of heavily immunodeficient
mice by crossing of SCID mice with non-obese diabetic (NOD)
mice and mice deficient in the gamma c (cc) chain of the IL-2
receptor or the generation of Rag1 or 22/2 cc2/2 knock-out
mice [8].
We and others demonstrated that these hu mice are highly
permissive to HIV infection when challenged with CCR5- or
CXCR4-tropic HIV strains and show viral dissemination and
progressive CD4+ T-cell loss [9,10,11,12,13].
To validate the experimental significance of hu mice for
studying HIV pathogenesis and their value for novel interventional
approaches, key aspects of HIV infection/pathogenesis must be
fulfilled. The model should recapitulate ART of disseminated HIV
infection with subsequent recovery of the immune system;
interruption of ART should result in a rebound of HIV replication
from the latent reservoir. Five studies reported the effects of ART
in HIV-infected humanized mice using different drugs and drug
combinations [14,15,16,17,18]. While these reports are very
promising that humanized mice may be the long awaited small
animal model for preclinical proof-of-concept studies, they lack
pharmacokinetic (PK) studies for the medicinal compounds used
except for the report by Choudhary et al [15] that would help to
compare the data obtained in humanized mice to a clinical
context.
A ‘‘standardized’’ ART scheme that completely suppresses HIV
RNA replication in hu mice would be highly valuable for pre-
clinical proof-of-concept studies for novel anti-retroviral com-
pounds and studies of latency that closely approximate the
situation in HIV-infected humans treated with ART.
Thus, we sought to determine if this mouse model is valuable for
studying antiretroviral treatment of disseminated HIV infection
and if it recapitulates key features, such as viral rebound, break-
through replication and viral rebound subsequent to interruption
of ART. We made a major effort to define the dose of
antiretroviral compounds added to the food pellets to compare
data to human studies. We also benefited from access to
antiretroviral compounds in special formulation that permit once
weekly dosing in mice. Thus, we also were able to study a novel
concept of anti-HIV therapy based on LA antiretroviral drugs.
Results
Engraftment with human cells at around week 15 when
hu mice were infected with HIV
Newborn NOG mice were transplanted with CD34+ haema-
topoietic progenitor cells isolated from umbilical cord blood. At
around 15 weeks of age, the engraftment level was 20.7%613.2
(avg 6 std) before HIV infection (Figure S1). Of all human cells,
CD4+ T cells were 23.1%614.5 (avg 6 std), CD8+ T cells
12.9%69, and CD19+ B cells 50.8%624.2. These engraftment
values and their cell subset distributions are similar as reported
previously [11,19,20].
Pharmacokinetics of 3TC, Tenofovir (TDF), TMC278-long-
acting (LA) and TMC181-LA
The easiest and most convenient way for long-term ART in hu
mice would be to add the ART to the food pellets. Mice have a
higher metabolism than humans, and thus, we converted the dose
of the distinct compounds used in humans by a formula as
described [21]. The dose calculated was 61.7 mg/kg/day for 3TC
and for TDF, considering food uptake of 3–4 g/d for a hu mouse
with a body weight of 20–30 g. We generated food pellets
containing 0.5 mg of 3TC and TDF per g of food. 3TC and TDF
belong to the group of nucleoside resp. nucleotide reverse
transcriptase inhibitors (NRTIs).
PK data validated this approach showing plasma levels in the
therapeutic range over the entire observation period with
fluctuations due to the wake-sleep cycle of the mice (Fig. 1A–D).
In contrast, azidothymidine (AZT) at 0.5 mg/g of food and
ritonavir (RTV) at 1 mg/g of food gave toxic concentrations
clearly above the therapeutic range or sub-inhibitory concentra-
tions, respectively (Figure S2). The plasma concentration of
TMC278-LA and TMC181-LA (at the higher dose) was still
clearly above the target concentration (Ctarget) even 14 days after
s.c. injection (Fig. 1E–F). TMC278 is the recently approved non-
nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine [22],
and TMC181 is a pre-clinical-stage protease inhibitor (PI)
belonging to the same chemical class as TMC114 (darunavir),
but displaying better potency while preserving similarly high
resistance coverage. The PK data of the long-acting drugs
permitted a once weekly application in mice.
HIV RNA plasma level is suppressed by ART and promptly
rebounds with treatment interruption
In a pilot experiment, uninfected mice appeared to tolerate
AZT, 3TC and RTV well. Thus, while awaiting the PK data of
these compounds, we started a first experiment to examine ART
in HIV-infected mice (Fig. 2). Mice before ART had an HIV RNA
baseline of 104.96105.2 copies/ml (avg 6 std). Unexpectedly, the
treated mice developed wasting within 2 weeks, which we
attributed to the ART and, in particular, AZT. We therefore
changed the ART immediately to TDF, 3TC and TMC278-LA,
and within 1 week, the mice recovered from the wasting disease.
Importantly, within 4–8 weeks, 14/21 (66%) mice showed a
decline of HIV RNA levels to under the detection limit of 800
copies/ml (Fig. 2A). One mouse with detectable HIV RNA at that
time showed suppressed HIV RNA when we bled it 72 days after
start of ART (Fig. 2A). Since we switched the ART in two mice
with detectable HIV RNA to monotherapy with TMC278-LA, we
are not able to make any statement about their eventual response
rate if the ART had been continued. Thus, the overall response
rate to the ART (3TC/TDF/TMC278-LA) was 79% (15/19
mice).
In an additional group of mice treated with AZT, 3TC and
RTV, we found various laboratory disturbances, most prominent
a very significant anemia (Figure S3). In concert with plasma AZT
levels clearly above the therapeutic range, we attributed the
wasting observed to AZT toxicity.
Nearly all mice receiving the 2 weeks of AZT, 3TC and RTV
treatment suffered from weight loss (Fig. 2E and F). Remarkably,
the mice with viral failure experienced more significant weight loss
than the others (Fig. 2G). Mock-treated HIV-infected mice showed
Treating HIV Infection in Humanized Mice
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a very stable weight course with fluctuations of less than 2 g over
time.
We subsequently divided the mice with suppressed HIV RNA
into two groups, seven mice were maintained on ART for another
5 weeks and, thereafter, treatment was interrupted. The other
seven mice were treated by TMC278-LA alone. ART interruption
resulted in viral rebound in all mice, indicating the existence of a
latent reservoir, such as that in HIV-infected humans (Fig. 2C).
Monotherapy with TMC278-LA was insufficiently potent to
suppress HIV RNA since 6/7 mice showed a breakthrough of
viral replication (Fig. 2D).
While there were no obvious symptoms or signs, we observed a
higher mortality in mock-treated HIV infected mice than in ART
treated mice. We associated this higher mortality with an unknown
HIV-associated phenomenon. This mortality was usually less than
20% and thus when working with small numbers of mice, there
Figure 1. PK data for 3TC, TDF, TMC278-LA and TMC181-LA. (A and C) Plasma levels of 3TC and TDF, respectively, over a day of mice on food
pellets containing 0.5 mg/g food of 3TC or TDF for 2 weeks. (B and D) Decay rate of 3TC (tK= 5.5 h) and TDF (tK= 3.5 h), respectively, when
replacing the food containing 3TC or TDF with standard food. (E and F) Plasma levels after one dose of either TMC278-LA (160 mg/kg) or TMC181-LA
(white dots: 200mg/kg; black dots: 400mg/kg) administered s.c. The data were obtained with mice on ART-containing food pellets for at least
2 weeks to permit PK equilibration. The shaded area in (A–D) indicates the therapeutic range as defined in humans [42,43]. The dashed line in (E and
F) indicates the target concentration (C target). Median effective concentration (EC) 50 values of TMC278 and TMC181 are 4.95 ng/ml and 1.29 ng/ml
respectively in vitro in MT4 cells cultured with 50% human serum. The different colours indicate the experiments done with the same food batch, and
whether we used mice transplanted with human CD34+ cells or not (White, red and yellow dots indicate humanized mice, green and blue dots
indicate mice without transplantation of human CD34+ cells).
doi:10.1371/journal.pone.0038853.g001
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may be divergence from this estimated mortality rate. In the 2nd
set of experiments presented (see below), we had no loss due to
‘‘spontaneous’’ mortality.
Emergence of drug-resistant HIV strains in hu mice
All mice on ART with 3TC, TDF and TMC278-LA which
experienced viral failure revealed the consecutive or simultaneous
emergence of the prototype 3TC mutation M184I and the
TMC278 mutation E138K (Fig. 3 and Table 1). All but one mouse
showed viral failure when treated with TMC278-LA monother-
apy. Of those mice with viral failure, all but one had the E138K
mutation either alone or with the M184I mutation (Table 1). It is
unknown if minor drug variants or mutations outside the amplified
RT region might explain the lack of any TMC278 resistance
mutation detected in the one mouse scored fully susceptible to
TMC278 [23].
ART with two long-acting drugs (TMC278-LA and
TMC181-LA) effectively treats HIV-infected hu-mice
Next, we sought to determine if a simplified ART of two long-
acting drugs interfering at different steps in the HIV replication
cycle is effective as maintenance therapy to keep HIV RNA under
the detection limit. Initial ART was with TDF, 3TC, TMC278-
LA and TMC181-LA. In mice with documented HIV RNA below
detection limit after 44 days of ART, we simplified the regimen as
planned. The other mice that still showed a marked viremia were
continued on the quadruple ART. The dual ART consisting of
TMC278-LA and TMC181-LA given once weekly s.c. was really
potent: all but one mouse (viral blip) had undetectable HIV RNA
(Fig. 4B). Note, that the HIV RNA of all mice which were
maintained on the quadruple ART became negative at 99 days
after start of treatment (Fig. 4A). This variable decay rate in
response to ART mirrors the distinct decay rate of HIV in patients
Figure 2. ART is highly efficient in disseminated high-titer HIV infection in hu mice. (A) Response to ART with AZT, 3TC and RTV, followed
by 3TC, TDF and TMC278-LA. Note that the initial regimen was poorly tolerated by the hu mice that resulted in reduced food uptake and thus a
somewhat lower response rate. (B) Mock-treated HIV-infected mice (n = 8). (C and D) Mice with suppressed HIV RNA were either kept on ART (n = 11)
(C) or switched to monotherapy with TMC278-LA alone (n = 10) (D). ART and monotherapy were interrupted to monitor the mice for viral rebound.
We included two mice with viral failure into the group treated with TMC-278-LA alone. |2 indicates that one mouse died within one week of bleeding.
(E and F) Weight monitoring of mice either constantly on combined ART (E) or switched subsequently to monotherapy with TMC278-LA (F).
Compilation of weight loss over time of all mice, i.e., mice on ART with viral failure (VF), mice on ART with suppressed HIV RNA and untreated HIV-
infected mice (controls) (G). Grey-spotted area indicates the time period hu mice were on ART with AZT, 3TC and RTV, grey-plain shaded the time
period on ART with 3TC, TDF and TMC278-LA. The coloured circles indicate the mice with viral failure.
doi:10.1371/journal.pone.0038853.g002
Figure 3. Humanized mice with viral failure under ART with 3TC, TDF and TMC278-LA show consecutive or simultaneous
emergence of the key mutation to 3TC or TMC278. A), B), C) and D) show the four mice with emergence of resistance under ART. The black
dots indicate that resistance testing had been done, white dots no resistance testing done.
doi:10.1371/journal.pone.0038853.g003
Treating HIV Infection in Humanized Mice
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e38853
starting ART. As expected the CD4/CD8 T-cell ratio was
significantly higher in the mice with suppressed HIV RNA than in
control mice (Fig. 4D).
ART-treated HIV-infected hu mice had HIV RNA under 50
copies/ml but detectable cell-associated HIV DNA
The limited amounts of blood in any running experiment held
the sensitivity of the Amplicor RocheH to 400–800 copies/ml.
Although it is unlikely, this detection limit does not exclude low
viral replication in the ART treated mice. The HIV RNA
measurement based on the final bleeding of the mice treated either
with the dual ART or the quadruple ART (3TC, TDF, TMC-
278LA, TMC181-LA) revealed that 8/10 mice had fewer than 60
copies/ml (Table 2), which emphasizes the efficacy of the ART in
the current setting.
In the mice from the second experiment (i.e., mice as shown in
Fig. 4), we determined if cell-associated HIV DNA was detectable
in splenocytes. Using a real-time PCR specific for YU-2, this was
indeed the case in 13/15 mice (Fig. 5A); in all untreated mice, we
detected levels of cell-associated HIV DNA higher than in treated
ones with the exception of mouse #417. This mouse showed a
low-level viremia despite ART that easily explains the relatively
high cell-associated HIV DNA. We observed no correlation
between cell-associated HIV DNA and engraftment levels or peak
viremia.
In vitro reactivation of HIV transcripts in spleen
specimens from hu mice in response to re-activating
compounds
In order to examine whether latently infected cells exist in hu
mice, we examined unspliced HIV Gag mRNA transcripts in
spleen specimens from HIV-infected mock- and vero-treated mice
prior and after in vitro reactivation. Since we were limited in spleen
specimens, we opted for a combination of mitogens in concert with
anti-CD3/CD28 and IL-7 to increase our chances of successful
reactivation. The short term assay we used as well as the anti-
apoptotic effect of IL-7 was certainly beneficial for counteracting
any toxic effects due to the application of such a cocktail. Indeed,
we did not observe any toxic effects 18 h after adding this cocktail
when we harvested the tissue for quantifying HIV mRNA
transcripts. As previously reported [16,17,18], we observed a
clear reactivation of HIV Gag transcripts after stimulation
(Fig. 5B). We did not isolate the human CD4+ cells to perform
in vitro reactivation studies – however, we have no reason to assume
that the cell subset harbouring latently HIV will differ from the
results published [16,17,18].
Discussion
We sought to determine if hu mice recapitulate key features of
HIV infection and treatment and to assess the value of long-acting
anti-HIV drugs for treating HIV infection. We found that i)
conventional ART with two NRTIs and a NNRTI efficiently
suppressed HIV viral load and allowed recovery of the immune
system; ii) cell-associated HIV DNA was still present in those mice,
and interruption of ART resulted in viral rebound; in vitro
reactivation of spleen specimens from successfully treated mice
yielded increased number of HIV mRNA transcripts as compared
to baseline; and iii) simplification of ART with two long-acting
drugs kept HIV RNA suppressed. Thus, HIV infection in hu mice
mirrors key features of HIV infection in humans, including high
titer viremia in untreated mice, suppression of HIV RNA when
treated with ART but emergence of resistance when treated with
insufficient regimens, viral rebound after treatment interruption,
and recovery of CD4+ T cells under ART. Thus, hu mice are a
highly valuable animal model to assess the antiviral potency of new
compounds or novel strategies to eradicate latent HIV.
Liv/thy SCID hu mice have been used before to investigate
novel compounds for their anti-HIV activity [5,24]. However,
detailed PK data were mostly lacking, thus making it difficult to
interpret the antiviral potency of the compounds. Furthermore,
conventional liv/thy SCID hu mice lack peripheral T cells [3].
Thus, SCID-hu Thy/Liv mice were rarely used to study
compounds to treat disseminated HIV infection. Most studies
administered the drugs either before or immediately after the HIV
challenge [25], and that recapitulates post- or pre-exposure
prophylaxis where less potent regimens are already effective.
The new generation of hu mice displays an elaborated
lymphoid-like system of human origin [6] and is highly susceptible
to HIV infection. However, studies with these mice lacked data
about their value for standardized pre-clinical testing. Five studies
[14,15,16,17,18] reported the efficacy of ART in HIV-infected
mice. In these studies, ART was started within 3 weeks after HIV
Table 1. Emergence of resistance in the mice under monotherapy with TMC278-LA.
Mouse
(Identifier)
day 30
(baseline)
day 73 (under ART
with 3TC, TDF,
TMC278-LA)
day 128 (38 days under
TMC278-LA alone)
day 150 (22 days after
interruption of TMC278-LA)
# 192** S* n.d." S S
# 242 S n.d. n.d. S
# 232 S n.d. E138K E138K
# 190*** S M184V n.d. M184I/E138K
# 189 S S M184I/K101E/E138K M184I/K101E/E138K
# 191*** S M184I M184I/E138K M184I/E138K
# 224*** S M184I n.d. M184I/E138K
*S = susceptible (wildtype strain).
**#192 showed suppressed HIV RNA under TMC278-LA monotherapy.
***#191, 224 showed viral failure under the ART regimen of 3TC, TDF and TMC278-LA. #190 gave a positive signal for HIV RNA but below the limit of detection (,800
copies/ml)
#221, 245 only baseline analyses have been done, and therefore data from these mice were not integrated in the table.
"#n.d. = not done.
doi:10.1371/journal.pone.0038853.t001
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infection (i.e., rather early after HIV challenge). In the first study,
HIV was suppressed in 3/6 mice by i.p. ART, and HIV recurred
when treatment was interrupted [15]. Surprisingly, a second study
did not observe viral rebound after treatment interruption [14]. In
subsequent studies, complete response rates were reported with an
intensified regimen (i.p. administration of emtricitabine (FTC),
TDF, an integrase inhibitor and enfuvirtide) [16] or high doses of
ART given i.p [17]. All but one [16] of these studies lack detailed
PK data on the administered drugs and data related to long-term
administration of ART and to the anti-HIV efficacy of ART in
chronically infected mice. Compared to the PK data we generated
in mice and considering the therapeutic range in humans, the
dosages applied in some of the studies reported are most likely 3–
5-fold over the therapeutic range.
For an effective mouse model, long-term ART must be non-
toxic and well tolerated by the mice. This requires solid PK data in
Figure 4. Two long-acting drugs, TMC278-LA (160 mg/kg) and TMC181-LA (400 mg/kg), are highly effective as maintenance
therapy. (A) Response to a quadruple ART consisting of 3TC, TDF, TMC278-LA and TMC181-LA over a treatment period of 150 days (the black circles
identifies the mice which remained over the entire time on ART (n = 7), the white circles identify the mice which were subsequently switched to a
treatment with double long-acting drugs (see (B)). (B) Sustained successful suppression of HIV RNA after switching mice with suppressed HIV RNA
under quadruple ART to a treatment with double long-acting drugs (n = 8). (C) Mock-treated HIV infected mice (n = 5). (D) CD4+ T-cells as determined
by the CD4/CD8 cell ratio in all treated mice (ART and double long-acting drugs) and mock-treated mice at the end of the experiment.
doi:10.1371/journal.pone.0038853.g004
Table 2. HIV RNA load at the terminal bleeding in mice on ART or on double long-acting drugs.
Mice on quadruple ART Mice on double-long acting drugs
Mouse identification number #411 #412 #417 #432 #459 #402 #413 #415 #457 #466
HIV RNA n.d.* n.d. 152 n.d. ,40 ,60 502 n.d. n.d. n.d.
Detection limit [copies/ml] 40 40 40 40 40 60 40 60 60 40
*n.d. = non-detectable.
- Humanized mice were sacrificed 151 days after HIV infection and 114 days after starting ART or double long-acting drugs.
- Detection limit: the volume of plasma available was slightly different for the mice euthanized and thus the lower detection limit varied accordingly between 40 and 60
copies/ml.
doi:10.1371/journal.pone.0038853.t002
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the therapeutic range for humans. In our experiments, we added
the distinct anti-HIV compounds to the food pellet based upon
calculating food intake, weight and metabolic rate. We generated
PK data in the therapeutic range for 3TC and TDF. The long-
acting drugs TMC278-LA and TMC181-LA were injected s.c.
once weekly. We identified dosages that resulted in concentrations
clearly above the Ctarget 1 week after its administration. Notably,
plasma levels of NRTIs approximate only the concentration of the
anti-HIV active intracellular tri-phosphorylated compounds. Since
the half-life of the active moiety is longer than from the parental
compound [26], we were confident that the dosages would be
efficacious for treating disseminated HIV infection in our model.
Indeed, this was the case. We observed HIV RNA suppression in
79% in the first and 100% in the second experiment.
From the PK data, the mice in the first experiment were treated
for the first 2 weeks with only effective dosages of 3TC and AZT, a
dual therapy insufficient to suppress HIV; RTV plasma levels were
substantially below the therapeutic range. Furthermore, AZT
which was toxic for the mice resulted in decreased food uptake that
was reflected by substantial weight loss and sub-therapeutic dose
levels. The emergence of drug-resistant HIV was a logical
consequence of insufficient ART plasma levels. The observed
M184I mutations in our study are the most prevalent among
TDF/FTC-treated HIV individuals. Furthermore, we selected the
TMC278 E138K resistance–associated mutation in our mouse
Figure 5. Recovery of cell-associated HIV DNA (A) and increase of HIV mRNA transcripts in vitro from splenic tissue obtained from
HIV-infected mice with suppressed HIV RNA following activation. (A) DNA from infected HeLa cells (HeLa inf) and from the spleen of HIV-
infected mice served as positive controls, DNA from an uninfected humanized mouse (uninf) served as negative control. The specimens of the treated
and HIV-infected mice were from the experiments investigating the antiviral potency of the double long-acting drugs; (MNE = mean normalized
expression). B) Splenic tissue specimens from either HIV infected ART naı¨ve hu mice (HIV), ART treated mice (ART) or mice treated with the two long
acting drugs (Double-LA) were subjected to mitogens (PMA, PHA) in concert with anti-CD3/28 and IL-7. 18 hours later RNA was extracted and real-
time PCR done for quantifying HIV Gag transcripts. Specimens of two mice which were treated with double LA drugs did not show any HIV transcript
at all (data not shown in the graph); in five mice we did not detect any HIV transcripts prior to stimulation. The real-time PCRs were done in
duplicates. *this specimen is from a mouse (#417) with detectable HIV RNA at the time of euthanization (see Table 2).
doi:10.1371/journal.pone.0038853.g005
Treating HIV Infection in Humanized Mice
PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e38853
model. These findings demonstrate that our model consistently
reproduced the Phase III trial results of the ECHO & THRIVE
studies, which showed that E138K and M184I combination was
the most observed resistance associated mutations in patients
treated with TMC278 and co-formulated TDF/FTC [27,28].
Indeed, our data indicate that the M184I mutation precedes the
E138K mutation; this suggests that patients with archived HIV
strains with the M184I are especially prone to viral failure with a
subsequent triple compound–based regimen with 3TC or FTC
and TMC278. This mimics what happens in patients with poor
adherence and emphasizes the preclinical proof-of concept value
of this mouse model for HIV infection.
HIV-infected mice displayed a distinct response rate to ART
(i.e., around 50% of all mice under quadruple therapy had an
undetectable HIV RNA at day 44, the other 50% at day 99)
(Fig. 4A). Since we were limited in blood draws, we have no
detailed data about the viral decay in these sets of mice. Notably,
we observed a rapid drop of HIV RNA in a majority of HIV-
infected mice within 10 days after initiation of ART when we took
blood in short intervals (unpublished data). In any case, the
response rate to ART may vary in HIV-infected hu mice similar to
the variable response observed in HIV-infected individuals starting
ART. It would be therefore sensible to perform HIV RNA
measurements over at least 2 months to document ART response
or failure.
In our experiments, blood draws yielded small amounts, but
terminal bleeds yields larger blood volumes, which are a critical
determinant for the sensitivity of the Amplicor RocheH. Indeed,
the larger blood volumes documented the success of ART with
HIV RNA copy numbers below 60/ml in most mice, thus
excluding that low-level viremia was still ongoing in the
successfully treated animals.
Interrupting ART resulted in prompt viral rebound in all mice.
The mice used for that purpose successfully responded to ART
and were treated for a longer period of time to assure the decay of
potentially low-replicating cells. We also found cell-associated HIV
proviral DNA in untreated and successfully treated mice, re-
enforcing the fact that HIV generates a latent reservoir in HIV-
infected hu mice. Besides, cell-associated HIV proviral DNA levels
in untreated mice were higher than in treated ones, similar to the
case in humans [29]. Similarly to findings reported [16,17,18], we
observed a clear increase of HIV transcripts when splenic tissue
from HIV infected mice with suppressed HIV RNA was
stimulated. These findings are promising for using hu mice for
studying the latent reservoir and in particular for studying
approaches to eradicate it. We observed no correlation between
cellular HIV-associated proviral DNA and engraftment level or
peak viremia. These data show that hu mice represent a model to
study latency and potentially novel treatment strategies. Viral
rebound or its absence in vivo will be a definitive end point of novel
eradication strategies aiming to cure HIV infection.
We also report the use of our HIV hu mouse model in the study
of TMC278 and TMC181 in a galenic formulation that results in
plasma levels above the Ctarget for at least 1 week after
administration (long-acting drugs) [30,31]. TMC278 corresponds
to the recently approved NNRTI, rilpivirine [32]. Note that
TMC181-LA is a prototype HIV long-acting protease inhibitor;
however, the compound is not itself a candidate for clinical
development. We tested TMC278-LA as adjunct to the backbone
of 3TC and TDF for treating disseminated HIV infection and
TMC278-LA alone or in combination with TMC181-LA for
maintenance therapy in mice with suppressed HIV RNA. As
expected, TMC278-LA was very potent in combination with the
NRTI backbone (see above). However, TMC278-LA as mono-
therapy was not sufficient to maintain HIV suppression. Indeed,
all mice showed a viral breakthrough. This prompt viral
breakthrough is consistent with the clinical experience in humans:
the NNRTI class must be given with a potent backbone [33].
Indeed, due to the long half-life of efavirenz (EFV) and nevirapine
(NVP), as opposed to other anti-HIV drugs, interruption of ART
containing either EFV or NVP at once results in a monotherapy
with the risk of the emergence of NNRTI-resistant strains [34,35].
This clinical observation documents the relatively low genetic
barrier of NNRTIs when given alone. In contrast, TMC278-LA in
concert with TMC181-LA was highly efficient with a response rate
close to 100% over time. In fact, clinical trials are under way to
examine simplification of ART (e.g., combination of the protease
inhibitor atazanavir and the integrase inhibitor raltegravir) [36].
Thus, this HIV mouse model would be superbly suited for a pre-
clinical proof-of-concept of novel ART strategies (e.g., nucleoside
sparing regimens, long-acting drugs).
Conclusions
In summary, we present data of ART responses/failures in
larger number of mice that eventually position this hu mouse
model as key tool in the evaluation of novel treatment strategies
and latency. Hu mice, indeed, recapitulate central steps in HIV
infection, including high-titer viral dissemination, response to
ART, viral failure in the case of non-adherence and very
importantly viral rebound after ART interruption. Viral rebound
after interruption of ART points clearly to a latent reservoir of
HIV. This model will be crucial when testing compounds for
activating the latent reservoir aiming to eradicate and eventually
cure HIV. We underscore this statement by documenting the
value of long-acting anti-HIV drugs for suppressing HIV that
might be very effective in certain clinical situations, e.g., PREP,
PEP or in patients with poor adherence, as a simplified
maintenance regimen, or in patients unable to swallow drugs.
Materials and Methods
Ethics statement
All experiments as well as procurement of human cord blood
were approved by ethical committees of the University of Zurich
and the Federal Veterinary Department and. The experiments
were conducted according to local guidelines (TschV, Zurich) and
the Swiss animal protection law (TschG). Human cord blood was
collected with informed written consent of the parents.
Generation of hu mice
Immunodeficient NOD/shi-scid/ccnull (NOG) [19] mice were
reconstituted and infected as described [9]. Briefly, newborn NOG
mice were irradiated 1–3 days after birth with 1 Gy and
subsequently injected intra-hepatically with 2.560.56105
CD34+ cells. CD34+ cells were isolated from human cord blood
with immunomagnetic beads (Miltenyi Biotec) with an yield of
0.5–46106 CD34+ cells from one donation (purity .90%).
CD34+ cells and ‘‘non-target’’ fractions were stored frozen in
liquid nitrogen until use. At around 15 weeks after transplantation,
the engraftment of human immune cells was checked by staining
peripheral blood mononuclear cells for the panhuman marker
CD45. In all experiments, mice were randomized into mock- or
ART treated groups.
Generation of food pellets containing anti-HIV drugs
Food pellets were made by mixing 2.5 g of 3TC, TDF and AZT
each, and 5 g of RTV with 5 kg of ground protein-rich, vitamin-
fortified food (Nafag 3432, Provimi Kliba AG, Switzerland) which
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was subsequently formed to food pellets and sterilized by gamma-
irradiation with 25 kGy. All batches of food pellets were analyzed
for the correct amount of drugs admixed by HPLC (see below).
Food and tap water were given ad libitum. TMC278-LA and
TMC181-LA were generated by wet milling the compounds to get
nanosizes and their subsequent formulation with non-ionic
surfactants [30,31]. They were injected s.c. at 160 and 400 mg/
kg, respectively.
HPLC-MS/MS method for measuring levels of TDF and
3TC in plasma and food pellets and TMC278 and TMC181
in plasma
Concentrations of drugs in the plasma and food pellets were
determined by a qualified research liquid chromatography and
mass spectroscopy (LC-MS/MS) method. For the analysis of diet,
food pellets were diluted with water (1:10) and homogenized.
Aliquots of each homogenate (50 mL) were solubilized with
methanol (three volumes) and extracted with an identical volume
of acetonitrile. Plasma samples (50 mL) were prepared identically
as the food pellet homogenates. Plasma and food pellets were
quantified using a specific LC-MS/MS method.
LC-MS/MS analysis was carried out on an API-4000 MS/MS
(Applied Biosystems), which was coupled to an HPLC system
(Agilent). The MS/MS was operated in the positive ion mode with
the TurboIonSpray-interface (electrospray ionization) and opti-
mized for the quantification of the compound (MRM transition for
TDF: 520.2.270; for 3TC 288.176; for TMC278 367.2.224
and for TMC181 585.2.429).
The calibration range was flexible and depended on the study
design. The limit of quantification was 0.5–10 ng/ml, depending
on the compound. The accuracy (intra-batch accuracy for
independent QC samples) was 80–120% of the nominal value
over the entire concentration range of the samples.
HIV infection and ART
Mice were infected i.p. with HIV YU-2, 16106 tissue-culture
infectious dose50 (TCID50) per mouse. TCID50 was determined in
human CD8+T cell depleted PBMC from three donors which
were stimulated by PHA and anti-CD3 beads (Dynal). HIV RNA
plasma levels were measured by RT-PCR (AmpliPrep/COBAS
TaqMan HIV-1 Test, Roche) at various times after infection.
Mice were monitored three times a week for symptoms or signs
of adverse events, according to a standard score sheet.
Flow cytometry
Human cells, T cells and B cells were measured by flow
cytometry of white blood cells stained for human CD45-APC,
CD4-PerCP-Cy5.5, CD8-PB, and CD19-PE-Cy7 (all from BD
Biosciences).
qPCR analysis of mouse organ samples
DNA and RNA from half of a spleen were extracted
simultaneously with the AllPrep DNA/RNA Kit (Qiagen). DNA
qPCR was as described [37], using HotStarTaq Master Mix
(Qiagen), 1 mM of each primer and 0.1 mM FH probe.
Experiments were done in duplicate with the real-time thermo-
cycler IQ5 (BioRad) and as cycling profile: 95uC 15 min, 606
(95uC 5 s, 55uC 5 s, 60uC 40 s). The following oligonucleotides
were used for HIV gag gene: mf319tq (probe): FAM59-TGC AGC
TTC CTC ATT GAT GGT-39TAMRA [38], ts59gag (sense): 59-
CAA GCA GCC ATG CAA ATG TTA AAA GA-39 [37] and
skcc (antisense) (59-TAC TAG TAG TTC CTG CTA TGT CAC
TTC C-39 [39]. The following oligonucleotides were used for the
reference gene GAPDH: mf70tq (probe): FAM59-AAG GTC
GGA GTC AAC GGA TTT GGT CGT-39TAMRA, mf45
(sense) 59-TCG ACA GTC AGC CGC ATC TT-39 and mf46
(antisense) 59-GGC AAC AAT ATC CAC TTT ACC AG-39.
Mean normalized expression (MNE) was calculated with qbase-
PLUS (version 2.0, Biogazelle). The following oligonucleotides
were used for HIV tat/rev gene mf84-YU-2 (sense) 59-ACA GTC
AGA CTC ATC AAA GTT CTC TAT CAA AGC A-39 [37],
mf226tq (probe): FAM59-AGG GGA CCC GAC AGG CCC-
39TAMRA [37] and mf83 (antisense): 59-GGA TCT GTC TCT
GTC TCT CTC TCC ACC-39 [37].
Since mice were infected with HIV-1 YU-2, the plasmid
encoding YU-2 was used as standard in the PCR reactions with a
detection limit down to 5 copies/reaction.
Reverse transcription
RNA was DNase treated using DNA-free kit (Ambion). For
reverse transcription random hexamer primers (Operon Technol-
ogies) and SuperScript III reverse transcriptase (Invitrogen) were
used. Reverse transcription was performed as described earlier
[40]; briefly cDNA synthesis was performed using 10 ml DNase
treated RNA in the presence of Ribolock Rnase inhibitor
(Fermentas) in a total volume of 50 ml as follows: 60 min at
50uC, 60 min at 55u, 15 min at 70uC and then 1 min on ice.
Subsequently 1 ml of RNAseH (NEB) was added to each tube and
incubated at 37uC for 20 min. Aliquots were stored at 220uC or
used immediately for real-time PCR analysis.
Ex vivo reactivation
Splenic cells of half of a spleen were thawed and split in two
equal parts and then incubated in RPMI containing fetal calf
serum (10%), IL-2 (10U/ml), penicillin (5%)/streptomycin (5%)
and L-glutamine (5%) at 37uC for 12 hours. Subsequently cells
were washed and then cultivated with or without mitogens (PHA
at 3 mg/ml, PMA at 10 ng/ml), anti-CD3/CD28 beads (Dyna-
beads, Invitrogen) and IL-7 at 20 ng/ml. 18 hours later, DNA and
RNA were extracted simultaneously with the AllPrep DNA/RNA
Kit (Qiagen) which was then used for quantifying the HIV mRNA
Gag transcripts.
Genotyping
Dideoxynucleotide-based sequence analysis was performed as
described [41]. Briefly, Dideoxy sequencing reactions were
performed on the purified amplicon (ABI Prism Big Dye
Terminator Cycle Sequencing Kit, Version 3.1, Applied Biosys-
tems) with a set of eight sequence-specific primers distributed over
the PR-RT sequence for both strands: F1, 59-GAGAGCTTCA
GGTTTGGGG-39; F2, 59-AATTGGGCCTGAAAATCC-39;
F3, 59-CCTCCATTCC TTTGGATGGG-39; F5, 59-
CACTCTTTGG CAACGACCC-39; R1, 59-CTCCCACTCAG-
GAATCC-39; R3, 59-CTTCCCAGAA GTCTTGAGTTC-39;
R5, 59-GGGTCATAAT ACACTCCATG-39; R6, 59-GGAA-
TATTGCTGGTGATCC-39. Reactions were purified with a
DyeEx Purification Protocol (Qiagen) and analysed with the
ABI3730xl DNA Analyzer (Applied Biosystems). Sequence data
files were grouped per sample identifier (ID) and aligned against
the reference HXB2 reference sequence by means of the
Sequencher TM Program V 4.1.4 (Gene Codes Corp.). A 25%
mixture scoring rule (similar to 20% mixture identification by 454
deep sequencing) was used for the electropherogram analysis.
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Calculations and statistics
Statistical analyses were performed using GraphPad Prism5.0
(GraphPad Software). Data were analysed by non-parametric
Mann-Whitney test. In all figures, points represent values of
individual mice, and lines depict mean values.
Supporting Information
Figure S1 Engraftment levels of hu mice before HIV
infection. The mice were checked for engraftment levels at a
median age of 132 days (25–75% percentiles: 103–136) as
quantified by staining peripheral blood for the panhuman marker
CD45. In addition, the percentage of CD4+, CD8+ and CD19+
cells were determined by flowcytometry.
(TIF)
Figure S2 PK data of AZT and RTV. (A and B) Plasma levels
of AZT and RTV, respectively, over a day of mice on food pellets
containing 0.5 mg/g or 1 mg/g food of AZT or RTV,
respectively. The mice used for analysis of PK data have been
on food pellets containing drugs for around 2 weeks for PK
equilibration. The shaded area indicates the therapeutic range as
defined in human. The different colours indicate the experiments
done with the same food batch.
(TIF)
Figure S3 AZT at the dose applied was highly toxic.Mice
were 2 weeks on a regimen with AZT as added at 0.5 mg/kg to
the food pellets and were subsequently euthanized. Extensive
laboratory chemistry and hematology work-up was done by the
Institute of Clinical Chemistry and the Division of Hematology,
USZ.
(TIF)
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